FDA approves Novartis kidney disease drug

Novartis Wins FDA Approval of Kisqali

FDA awards Novartis expanded approval for breast cancer therapy

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.

precisionmedicineonline · 2d

FDA Approves Novartis' Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer

The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.

Business Insider · 2d

Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential and FDA Approval

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price

UPI News on MSN · 2d

FDA expands use of Kisqali to early stage breast cancer patients

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Pharmaceutical Technology · 2d

FDA expands Novartis’ Kisqali label to include early breast cancer patients

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Zacks.com on MSN · 2d

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence,

MedCity News14d

Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... them a Novartis drug recently awarded accelerated ...

Scientific American2d

New Sickle Cell Treatments Reach Patients after Years of Effort

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

pharmaphorum7d

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second ... are at risk of rapid disease progression, making it the first complement inhibitor for the rare kidney disease.

FiercePharma14d

Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with Novartis

The FDA has converted ... measure of kidney function, with elevated levels being associated with serious kidney disease. The drug was the first non-immunosuppressive drug approved for ...

STAT7d

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Nasdaq11d

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney ...

PMLiVE11d

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to ...

NBC266d

FDA approves new Alzheimer's drug to slow disease progression

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending on Bing

Related topics